Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission

This study aimed to investigate the usefulness of allogeneic stem cell transplantation (allo‐SCT) for Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) in the first complete remission (CR1) with complete molecular remission (CMR). We compared the outcomes between Ph+ALL patients who did or did not undergo allo‐SCT in CR1. We included patients enrolled in the prospective clinical studies in the tyrosine kinase inhibitor era conducted by the Japan Adult Leukemia Study Group, who achieved CMR within 3 months. A total of 147 patients (allo‐SCT: 101; non‐SCT: 46) were eligible for this analysis. In the multivariate analyses, allo‐SCT was significantly associated with both superior overall survival (OS) (adjusted hazard ratio (aHR): 0.54; 95% CI: 0.30–0.97; p = .04) and relapse‐free survival (RFS) (aHR: 0.21; 95% CI: 0.12–0.38; p